Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons ing. T. Bos

Publicaties

Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach

Hepatocyte-specific Cas9-mediated editing of G6pc and Slc37a4 elicits comparable biochemical and regulatory responses between glycogen storage disease (GSD) type Ia and Ib mice

Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency

Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production

Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia

Disrupted glucose-6-phosphate-ChREBP signalling aggravates hepatomegaly and accelerates liver disease progression in a mouse model for Glycogen Storage Disease type 1a

Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing

Glucose-6-phosphate regulates hepatic bile acid synthesis in mice

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 6 – Schoon water en sanitaire voorzieningen

Meer informatie over de Sustainable Development Goals.